Last reviewed 2026-05-18 · How we verify

DTP Vaccine at 9 months of age

Medical Research Council Unit, The Gambia · Phase 1 active Biologic Quality 0/100

DTP Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia. It is currently in Phase 1 development. Also known as: DTP.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DTP Vaccine at 9 months of age
Also known as	DTP
Sponsor	Medical Research Council Unit, The Gambia
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DTP Vaccine at 9 months of age CI brief — competitive landscape report
DTP Vaccine at 9 months of age updates RSS · CI watch RSS
Medical Research Council Unit, The Gambia portfolio CI

Frequently asked questions about DTP Vaccine at 9 months of age

What is DTP Vaccine at 9 months of age?

DTP Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia.

Who makes DTP Vaccine at 9 months of age?

DTP Vaccine at 9 months of age is developed by Medical Research Council Unit, The Gambia (see full Medical Research Council Unit, The Gambia pipeline at /company/medical-research-council-unit-the-gambia).

Is DTP Vaccine at 9 months of age also known as anything else?

DTP Vaccine at 9 months of age is also known as DTP.

What development phase is DTP Vaccine at 9 months of age in?

DTP Vaccine at 9 months of age is in Phase 1.

Manufacturer: Medical Research Council Unit, The Gambia — full pipeline
Also known as: DTP

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing